The Goldman Sachs Group Issues Positive Forecast for Bicara Therapeutics (NASDAQ:BCAX) Stock Price

Bicara Therapeutics (NASDAQ:BCAX) had its price target lifted by The Goldman Sachs Group from $14.00 to $16.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities analysts also recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday. Citizens Jmp restated a “market outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday. HC Wainwright lifted their target price on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Finally, BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Eight equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Bicara Therapeutics Trading Up 4.5%

Shares of BCAX stock opened at $19.89 on Tuesday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $20.25. The stock has a market cap of $1.09 billion, a P/E ratio of -7.86 and a beta of -0.78. The company has a 50 day simple moving average of $17.21 and a two-hundred day simple moving average of $16.67.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.04. As a group, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current year.

Insider Activity at Bicara Therapeutics

In other news, insider David Raben sold 16,300 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the transaction, the insider owned 55,286 shares of the company’s stock, valued at approximately $1,023,896.72. The trade was a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Claire Mazumdar sold 1,596 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $18.95, for a total value of $30,244.20. Following the transaction, the chief executive officer owned 339,392 shares of the company’s stock, valued at approximately $6,431,478.40. The trade was a 0.47% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 137,969 shares of company stock worth $2,586,198.

Institutional Trading of Bicara Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $45,000. Legal & General Group Plc grew its holdings in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the last quarter. Larson Financial Group LLC increased its position in Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares in the last quarter.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Phase‑3 advancement and clinical catalysts: Bicara selected a 1,500 mg weekly dose of ficerafusp alfa and has initiated the pivotal FORTIFI‑HN01 trial with interim Phase‑3 readout expected mid‑2027; long‑term Phase‑1b follow‑up is slated for ASCO 2026 — these program milestones underpin upside potential. Article Title
• Positive Sentiment: Corporate update & financials: Q4/FY‑2025 release highlighted a strong cash position, selection of the Phase‑3 dose, and a less‑frequent dosing regimen in development — gives runway to reach clinical milestones. Article Title
• Positive Sentiment: Strong buy-side analyst support from some firms: HC Wainwright reiterated a Buy and boosted its PT to $42; Citizens Jmp and Wedbush reaffirmed market/outperform views with $31 and $30 targets — these bulls can attract momentum buyers. Article Title
• Neutral Sentiment: Modest Q4 beat: Bicara reported EPS of ($0.68) vs. consensus ($0.72) — a small beat but still operating at losses as expected for a clinical‑stage biotech. Press Release
• Neutral Sentiment: Mixed mid‑range analyst moves: Goldman Sachs and Wells Fargo raised price targets to $16 but kept Neutral/Equal‑Weight ratings (their PTs sit below the current trading level), which tempers upside for cautious investors. Article Title
• Negative Sentiment: Insider sale: CEO Claire Mazumdar sold ~8,234 shares (~$154k) in early March, trimming her direct holdings — a small insider sale but some investors view insider selling as a cautionary signal. Article Title

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.